SYNEXUS CLINICAL RESEARCH LIMITED
Get an alert when SYNEXUS CLINICAL RESEARCH LIMITED files next
Leroy will email you the moment a new filing lands at Companies House — one short note per filing, nothing else.
Cash
£3.1m
USD 4,219,000
-42.7% lowest in 6 filed years
Net assets
£28m
USD 38,154,000
+177.2% highest in 6 filed years
Employees
14
0% vs 2024
Profit before tax
-£23m
USD -31,177,000
-148.2% lowest in 6 filed years
Net assets
6-year trend · vs Industrials median
Accounts
6-year trend · Δ = latest vs prior filed period · latest reflected 2025-12-31
| Metric | Trend | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 | Δ vs prior |
|---|---|---|---|---|---|---|---|---|
| Turnover | £92,675,000 | £110,700,000 | £76,426,000 | £39,056,856 | £38,123,374 | £30,430,323 | -20.2% | |
| Operating profit | -£14,045,000 | £1,082,000 | -£9,134,000 | -£17,433,668 | -£7,311,037 | -£19,975,474 | -173.2% | |
| Profit before tax | -£14,687,000 | £259,000 | -£8,806,000 | -£16,981,791 | -£9,334,077 | -£23,171,312 | -148.2% | |
| Net profit | -£15,019,000 | -£200,000 | -£9,153,000 | -£18,470,457 | -£9,785,953 | -£21,215,162 | -116.8% | |
| Cash | £18,933,000 | £9,004,000 | £37,179,000 | £8,425,121 | £5,476,031 | £3,135,637 | -42.7% | |
| Total assets less current liabilities | -£2,716,000 | -£2,916,000 | -£12,069,000 | -£27,065,032 | -£36,745,448 | £28,356,745 | +177.2% | |
| Net assets | -£2,716,000 | -£2,916,000 | -£12,069,000 | -£27,065,032 | -£36,745,448 | £28,356,745 | +177.2% | |
| Equity | -£2,716,000 | -£2,916,000 | -£12,069,000 | -£27,065,032 | -£36,745,448 | £28,356,745 | +177.2% | |
| Average employees | 42 | 20 | 18 | 15 | 14 | 14 | 0% | |
| Wages | £3,600,000 | £2,164,000 | £1,393,000 | £1,099,220 | £1,045,708 | £1,341,509 | +28.3% | |
| Directors' remuneration | £189,000 | £144,000 | — | — | — | — | — |
Figures converted to GBP from USD at 0.743 per USD (Frankfurter spot rate) — hover any figure for the original. — indicates the figure wasn't present under that line item in that period. The Δ column is the change from the prior filed period as a percentage of |prior|; lines a company doesn't report show —. About these numbers
Ratios
Computed from the line items above — sparklines read oldest → newest
| Ratio | Trend | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|---|---|---|
| Operating margin | -15.2% | 1.0% | -12.0% | -44.6% | -19.2% | -65.6% | |
| Net margin | -16.2% | -0.2% | -12.0% | -47.3% | -25.7% | -69.7% | |
| Return on capital employed | — | — | — | — | — | -70.4% | |
| Current ratio | — | — | — | 0.43x | 0.38x | 1.49x | |
| Interest cover | -11.76x | 0.91x | -27.51x | -66.83x | -3.03x | -5.84x |
Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.
Name history
Renamed 1 time since incorporation
- SYNEXUS CLINICAL RESEARCH LIMITED 2008-06-30 → present
- SYNEXUS CLINICAL RESEARCH PLC 2005-09-27 → 2008-06-30
Audit & accounting basis
- Accounting basis
- FRS 102
- Reporting scope
- Standalone (parent only)
- Auditor
- Mitchell Charlesworth (Audit) Limited
- Audit opinion
- Unqualified (clean)
- Going concern
- Affirmed
“The directors have a reasonable expectation that the Company has adequate resources to continue in operational existence for the foreseeable future. They adopt the going concern basis, relying on the ongoing support of the parent group. Thermo Fisher Scientific Inc confirmed it intends to support the company for at least 12 months after financial statements approval.”
Group structure
- SYNEXUS CLINICAL RESEARCH LIMITED · parent
- Synexus Limited 100%
- Synexus Polska sp z.o.o 100%
- Synexus Clinical Research SA (Pty) Limited 100%
- Synexus Magyarorszag Kft 100%
- Synexus Clinical Research GmbH 100%
- Synexus Ukraine Limited Liability Company 100%
- Synexus Bulgaria 100%
- Medical Centre Synexus Sofia EOOD* 100%
- Synexus Czeh s.r.o 100%
Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers
People
6 active · 29 resigned
| Name | Role | Appointed | Born | Nationality |
|---|---|---|---|---|
| OAKWOOD CORPORATE SECRETARY LIMITED | Corporate Secretary | 2022-11-29 | — | — |
| AHMED, Syed Waqas | Director | 2023-03-29 | Nov 1979 | British |
| CAMERON, Euan Daney Ross | Director | 2023-03-29 | Mar 1976 | British |
| GREEN, Georgina Adams | Director | 2024-04-18 | Mar 1970 | British |
| SMITH, Anthony Hugh | Director | 2023-03-29 | May 1962 | American |
| STARR, Alison Jane | Director | 2024-04-18 | Jan 1977 | British |
Show 29 resigned officers
| Name | Role | Appointed | Resigned |
|---|---|---|---|
| GREGG, Rhona | Secretary | 2022-11-29 | 2026-03-31 |
| MCCLUSKEY, Paul | Secretary | 2007-06-28 | 2011-06-30 |
| NEILSON, Christopher | Secretary | 2005-09-27 | 2006-09-04 |
| HALLIWELLS SECRETARIES LIMITED | Corporate Nominee Secretary | 2006-09-04 | 2007-06-28 |
| SECRETARIAL APPOINTMENTS LIMITED | Corporate Nominee Secretary | 2005-09-27 | 2005-09-27 |
| BERG, Jason James | Director | 2023-01-31 | 2023-03-29 |
| BERTHOUX, Christophe | Director | 2010-09-13 | 2016-05-31 |
| BOYCE, Alan James | Director | 2007-02-19 | 2008-03-31 |
| CHAMBERS, Paul Michael | Director | 2016-10-18 | 2017-10-10 |
| CHAMBERS, Paul Michael | Director | 2011-09-23 | 2016-05-31 |
| FORT, Michael John | Director | 2005-09-27 | 2011-04-08 |
| GONDEK, Marcin | Director | 2017-10-10 | 2019-09-13 |
| HARRIS, Richard Stuart | Director | 2021-06-30 | 2023-03-29 |
| HARTMAN, Brainard Judd | Director | 2016-05-31 | 2019-09-13 |
| HUGHES, Malcolm Keith | Director | 2006-06-06 | 2007-12-05 |
| JAMES, Julia Mary | Director | 2016-05-31 | 2023-05-24 |
| MCCLUSKEY, Paul | Director | 2006-09-18 | 2011-06-30 |
| MISCAMPBELL, Ian Alexander Francis | Director | 2005-10-01 | 2007-12-05 |
| NEILD, Christopher David | Director | 2016-05-31 | 2020-03-19 |
| NEILSON, Christopher | Director | 2005-09-27 | 2006-09-15 |
| NORMAN, David John | Director | 2023-03-29 | 2024-04-18 |
| OWEN, Dustin Nathan | Director | 2021-06-30 | 2023-01-31 |
| PELLEGRINO, Jill Marie | Director | 2020-06-30 | 2021-06-30 |
| REDMOND, Michael | Director | 2005-09-27 | 2007-07-19 |
| SMITH, Ian Geoffrey | Director | 2005-09-27 | 2007-12-05 |
| SMITH, Roger Dale | Director | 2019-09-12 | 2020-06-30 |
| TONDER, Riaan Van | Director | 2019-09-12 | 2021-06-30 |
| CORPORATE APPOINTMENTS LIMITED | Corporate Nominee Director | 2005-09-27 | 2005-09-27 |
| SECRETARIAL APPOINTMENTS LIMITED | Corporate Nominee Director | 2005-09-27 | 2007-12-05 |
Ownership
Persons with significant control
| Name | Kind | Nature of control | Notified | Status |
|---|---|---|---|---|
| Synexus Clinical Research Midco No 1 Limited | Corporate entity | Shares 75–100%, Voting 75–100%, Appoints directors | 2016-08-31 | Active |
| Synexus Clinical Research Acquisitions Limited | Corporate entity | Shares 75–100%, Voting 75–100%, Appoints directors | 2016-04-06 | Ceased 2016-08-31 |
| Synexus Clinical Research Acquisitions Limited | Corporate entity | Shares 75–100%, Voting 75–100%, Appoints directors | 2016-04-06 | Ceased 2016-08-31 |
Filing timeline
Last 20 of 214 total filings
Material constitutional events — rename, articles re-file, resolution
- 2025-12-30 RESOLUTIONS Resolution
- 2025-12-20 RESOLUTIONS Resolution
- 2025-12-20 RESOLUTIONS Resolution
| Date | Type | Category | Description | |
|---|---|---|---|---|
| 2026-07-13 | AA | accounts | Accounts with accounts type full | |
| 2026-06-23 | CS01 | confirmation-statement | Confirmation statement with updates | |
| 2026-04-01 | TM02 | officers | Termination secretary company with name termination date | |
| 2026-01-30 | SH19 | capital | Capital statement capital company with date currency figure | |
| 2025-12-30 | SH19 | capital | Capital statement capital company with date currency figure | |
| 2025-12-30 | SH20 | capital | Legacy | |
| 2025-12-30 | CAP-SS | insolvency | Legacy | |
| 2025-12-30 | RESOLUTIONS | resolution | Resolution | |
| 2025-12-20 | RESOLUTIONS | resolution | Resolution | |
| 2025-12-20 | RESOLUTIONS | resolution | Resolution | |
| 2025-12-19 | SH01 | capital | Capital allotment shares | |
| 2025-07-28 | AA | accounts | Accounts with accounts type full | |
| 2025-06-23 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2024-11-11 | AA | accounts | Accounts with accounts type full | |
| 2024-06-24 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2024-04-23 | AP01 | officers | Appoint person director company with name date | |
| 2024-04-19 | AP01 | officers | Appoint person director company with name date | |
| 2024-04-19 | TM01 | officers | Termination director company with name termination date | |
| 2023-12-20 | AA | accounts | Accounts with accounts type full | |
| 2023-06-23 | CS01 | confirmation-statement | Confirmation statement with no updates |
Public-record activity
Raw counts from Companies House — last 12–24 months
- Filings
- 11
- Capital events
- 4
- Officers appointed
- 0
- Officers resigned
- 1
last 12 months
last 24 months
last 12 months
last 12 months
Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.